Zymeworks Announces Participation in Upcoming Investor Conferences
21 November 2024 - 12:05PM
UK Regulatory
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE
NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage
biotechnology company developing a diverse pipeline of novel,
multifunctional biotherapeutics to improve the standard of care for
difficult-to-treat diseases, today announced that management will
participate in the following upcoming investor conferences:
- Piper Sandler 36th Annual Healthcare Conference:
Zymeworks’ management will participate in one-on-one meetings and
present on December 3 at 1:30 pm Eastern Time (ET) in New York,
NY.
- Citi's 2024 Global Healthcare Conference: Zymeworks’ management
will participate in one-on-one meetings and a panel discussion
titled: ‘Novel Antibody Mechanisms in Oncology’ on December 3 at
3:15 pm ET in Miami, FL.
- 7th Annual Evercore HealthCONx Conference:
Zymeworks’ management will participate in one-on-one meetings and a
fireside chat on December 4 at 7:55 am ET in Coral Gables, FL.
- 43rd Annual J.P. Morgan Healthcare Conference:
Zymeworks’ management will participate in one-on-one meetings on
January 13-16, 2025, and a corporate presentation on January 16 at
8:15 am Pacific Time (PT) in San Francisco, CA.
In addition, Zymeworks will present an update on its preclinical
research programs at their Research & Development Day, taking
place virtually and in-person on December 12, 2024, in New York,
NY. This event, led by Paul Moore, PhD, Zymeworks’ Chief Scientific
Officer, will feature:
- Updates on our portfolio of solid tumor targeting antibody-drug
conjugates and T-cell Engager (TCE) molecules, featuring key
opinion leaders from these therapeutic areas who will join the
Company’s management team to discuss ongoing R&D and clinical
activities;
- Candidate nomination from our Trispecific TCE platform as the
last product candidate in our '5 by 5' R&D strategy; and
- Strategy and rationale for potential expansion into new
therapeutic areas in hematological cancers and autoimmune and
inflammatory diseases and preclinical development progress on
potential investigational new drug applications for new product
candidates in 2026 and beyond.
To register your participation for Zymeworks’ Research &
Development Day, please click here.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company
committed to the discovery, development, and commercialization of
novel, multifunctional biotherapeutics. Zymeworks’ mission is to
make a meaningful difference in the lives of people impacted by
difficult-to-treat cancers and other diseases. The Company’s
complementary therapeutic platforms and fully integrated drug
development engine provide the flexibility and compatibility to
precisely engineer and develop highly differentiated antibody-based
therapeutic candidates. Zymeworks engineered and developed
zanidatamab, a HER2-targeted bispecific antibody using the
Company’s proprietary Azymetric™ technology. Zymeworks has entered
into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz
Pharmaceuticals Ireland Limited (Jazz), granting each exclusive
rights to develop and commercialize zanidatamab in different
territories. Zanidatamab is currently being evaluated in multiple
global clinical trials as a potential best-in-class treatment for
patients with HER2-expressing cancers. The U.S. FDA granted
accelerated approval of Ziihera® (zanidatamab-hrii)
50mg/mL for injection for intravenous use for the treatment of
adults with previously-treated, unresectable or metastatic
HER2-positive (IHC 3+) biliary tract cancer (BTC). Ziihera is the
first and only dual HER2-targeted bispecific antibody approved for
HER2-positive BTC in the U.S. A BLA has also been accepted for
review by the Center for Drug Evaluation (CDE) of the National
Medical Products Administration (NMPA) in China. Zymeworks is
rapidly advancing a robust pipeline of wholly-owned product
candidates, leveraging its expertise in both antibody-drug
conjugates and multispecific antibody therapeutics targeting novel
pathways in areas of significant unmet medical need. Phase 1
studies for ZW171 and ZW191 are now actively recruiting with
investigational new drug applications for ZW220 and ZW251 planned
for 2025. In addition to Zymeworks’ pipeline, its therapeutic
platforms have been further leveraged through strategic
partnerships with global biopharmaceutical companies. For
information about Zymeworks, visit www.zymeworks.com and follow
@ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
Zymeworks BC (TG:ZA8)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Zymeworks BC (TG:ZA8)
Historical Stock Chart
Von Dez 2023 bis Dez 2024